Foundayo™

Foundayo (orforglipron) is the only oral GLP-1 medication for weight loss that can be taken any time of day without food or water restrictions. Unlike injectable GLP-1 options such as Wegovy and Zepbound, Foundayo is a once-daily tablet that requires no injections. It's also chemically different — a small-molecule compound rather than a peptide — which is what allows the flexible dosing. Compared to the Wegovy Pill (oral semaglutide), which must be taken first thing in the morning on an empty stomach with minimal water, Foundayo offers significantly more convenience.

In the ATTAIN-1 clinical trial, participants on the approved 17.2 mg dose lost an average of approximately 11% of their body weight (about 25 pounds) over 72 weeks. About 55% of participants at this dose lost at least 10% of their body weight. (The trial also tested higher investigational doses not included in the approved labeling.) Individual results vary based on factors like diet, exercise, starting weight, and overall health. At PEAK, Foundayo is always paired with nutrition counseling to maximize results.

The most common side effects are gastrointestinal: nausea (affecting up to 35% of patients in studies), diarrhea, constipation, and indigestion. These are generally mild to moderate and tend to improve over time, especially with PEAK's gradual titration approach. More serious but rare side effects include pancreatitis, gallbladder problems, and kidney injury related to dehydration. Your clinician will monitor for side effects and adjust your treatment plan as needed.

As a newly approved medication (April 2026), insurance formulary coverage for Foundayo is still being established across carriers. PEAK accepts Anthem, Cigna, Aetna, UnitedHealthcare, Sentara, and TRICARE, and does not accept Medicare or Medicaid. PEAK handles the prior authorization process for you and will confirm coverage before you begin treatment. If Foundayo isn't yet covered by your plan, your clinician may recommend an alternative or discuss cash-pay options through LillyDirect. View our full insurance and pricing information.

Foundayo's average weight loss (~11% at the approved 17.2 mg dose) is meaningful but less than Zepbound (~22.5% in SURMOUNT-1) and Wegovy (~15% in STEP-1). The primary advantage of Foundayo is its oral formulation with no food or water restrictions — making it an excellent option for patients who prefer not to inject or who had difficulty with oral semaglutide's strict dosing requirements. Your PEAK clinician will help you weigh the trade-offs between convenience and efficacy based on your goals.

Yes. If you are currently on Wegovy, Zepbound, or another injectable GLP-1, your PEAK clinician can help you transition to Foundayo. Early data from Lilly's ATTAIN-MAINTAIN study suggest patients can maintain weight loss when switching from injectable GLP-1 therapy to oral orforglipron, though that study used investigational 24 mg and 36 mg maintenance doses that are not commercially available — the FDA-approved maximum is 17.2 mg. Results at the marketed dose may differ. Your clinician will work with you on a dosing plan and monitor your response during the transition.